Because MCF7 MAGI1 KO cells showed defects in their DNA repair machinery, we tested whether olaparib, a PARP1 inhibitor used in patients to treat certain subtypes of breast and ovarian cancers, would render MCF7 MAGI1 KO cells more sensitive to cisplatin. This evidence concerns the gene MAGI1 and ovarian carcinoma.